Cowen upgraded shares of Hologic (NASDAQ:HOLX) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has $64.00 price target on the medical equipment provider’s stock.

Several other equities analysts have also weighed in on HOLX. BTIG Research reissued a buy rating and set a $60.00 price objective on shares of Hologic in a report on Friday, June 26th. UBS Group reduced their price objective on Hologic from $58.00 to $52.00 and set a neutral rating for the company in a report on Tuesday, April 28th. Barclays reduced their price objective on Hologic from $51.00 to $43.00 and set an equal weight rating for the company in a report on Thursday, March 26th. SVB Leerink raised Hologic from a market perform rating to an outperform rating and increased their price objective for the company from $41.00 to $62.00 in a report on Thursday, April 30th. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $45.00 to $55.00 and gave the company an overweight rating in a report on Thursday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $57.06.

Shares of HOLX stock traded up $0.89 during trading on Tuesday, hitting $57.86. The company’s stock had a trading volume of 3,004,417 shares, compared to its average volume of 2,827,039. The company has a market cap of $14.71 billion, a PE ratio of 25.27, a P/E/G ratio of 3.50 and a beta of 1.47. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 1.32. The business has a fifty day moving average of $52.90 and a 200-day moving average of $48.93. Hologic has a 52 week low of $26.49 and a 52 week high of $58.72.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, April 29th. The medical equipment provider reported $0.57 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.57. Hologic had a return on equity of 30.49% and a net margin of 18.53%. The company had revenue of $756.10 million during the quarter, compared to analyst estimates of $756.10 million. During the same period in the prior year, the company posted $0.58 earnings per share. As a group, research analysts predict that Hologic will post 2.32 EPS for the current year.

In related news, CEO Stephen P. Macmillan sold 190,996 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $50.97, for a total value of $9,735,066.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel John M. Griffin sold 4,906 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.00, for a total value of $245,300.00. The disclosure for this sale can be found here. Insiders sold 248,838 shares of company stock worth $12,752,550 in the last quarter. 1.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Norges Bank purchased a new stake in Hologic during the fourth quarter valued at about $153,506,000. Marshall Wace North America L.P. raised its position in Hologic by 5,553.7% during the fourth quarter. Marshall Wace North America L.P. now owns 2,008,974 shares of the medical equipment provider’s stock valued at $104,889,000 after purchasing an additional 1,973,440 shares in the last quarter. Point72 Asset Management L.P. raised its position in Hologic by 689.9% during the fourth quarter. Point72 Asset Management L.P. now owns 1,778,628 shares of the medical equipment provider’s stock valued at $92,862,000 after purchasing an additional 1,553,457 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in Hologic during the first quarter valued at about $34,864,000. Finally, Prudential Financial Inc. raised its position in Hologic by 56.9% during the fourth quarter. Prudential Financial Inc. now owns 2,334,937 shares of the medical equipment provider’s stock valued at $121,907,000 after purchasing an additional 847,038 shares in the last quarter. Institutional investors and hedge funds own 92.45% of the company’s stock.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: What is a closed-end mutual fund (CEF)?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.